Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma (NCT06677931) | Clinical Trial Compass
CompletedNot Applicable
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Melasma
China30 participantsStarted 2024-08-28
Plain-language summary
Melasma is a refractory skin disease with a complex pathogenesis and difficult treatment. Research has found that mesenchymal stem cell-derived exosomes have effects such as anti-wrinkle formation, anti-inflammation, antioxidant properties, skin whitening, and promotion of skin regeneration. Recent studies show that there is damage to the basement membrane in melasma skin lesions, and the regenerative repair function of mesenchymal stem cell-derived exosomes can repair the damaged basement membrane in melasma skin lesions, thereby effectively treating melasma. This study aims to observe the therapeutic effect of umbilical cord mesenchymal stem cell-derived exosomes combined with 1565 non-ablative fractional laser treatment for melasma, verify the enhancement effect of 1565 non-ablative fractional laser, and also explore a new combined treatment method for melasma that is effective, low in side effects, low in recurrence rate, and provides good patient comfort.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 to 60 years with good overall health.
✓. Diagnosed with melasma according to clinical diagnostic criteria and efficacy standards (revised edition), with facial skin lesions.
✓. Fully understands and comprehends the content and significance of the study, implementation plan, potential benefits, risks, mitigation measures, participant rights and obligations (including privacy protection and voluntary withdrawal), and willingly signs the informed consent form to participate in the clinical study, and can cooperate well.
Exclusion criteria
✕. Agrees not to use other cosmetic treatments related to the study during the research period.
✕. Patients who refuse to sign the informed consent form to participate in the trial.
✕. History of significant organ diseases, autoimmune diseases, or immune dysfunction.
✕. Abnormal coagulation function, current use of anticoagulants, tendency for thrombosis, or family history of genetic diseases.
✕. Pregnant or lactating women.
What they're measuring
1
melasma area and severity index, MASI
Timeframe: 1, 2, 3, 4, 5, 6, 7, 8 months after the first treatment